Cargando…
S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428431/ http://dx.doi.org/10.1097/01.HS9.0000967584.99278.43 |
| _version_ | 1785090467595026432 |
|---|---|
| author | Passamonti, Francesco Patriarca, Andrea Knapper, Steven Rivera, Candido Scandura, Joseph M Devos, Timothy Granacher, Nikki Mead, Adam Oh, Stephen Palmer, Jeanne Rampal, Raajit K Teichmann, Lino LI, Qing Eliane, Jean-Pierre Chang, Tzuu-Wang Klein, Sandra Colak, Gozde Harrison, Claire |
| author_facet | Passamonti, Francesco Patriarca, Andrea Knapper, Steven Rivera, Candido Scandura, Joseph M Devos, Timothy Granacher, Nikki Mead, Adam Oh, Stephen Palmer, Jeanne Rampal, Raajit K Teichmann, Lino LI, Qing Eliane, Jean-Pierre Chang, Tzuu-Wang Klein, Sandra Colak, Gozde Harrison, Claire |
| author_sort | Passamonti, Francesco |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428431 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104284312023-08-17 S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY Passamonti, Francesco Patriarca, Andrea Knapper, Steven Rivera, Candido Scandura, Joseph M Devos, Timothy Granacher, Nikki Mead, Adam Oh, Stephen Palmer, Jeanne Rampal, Raajit K Teichmann, Lino LI, Qing Eliane, Jean-Pierre Chang, Tzuu-Wang Klein, Sandra Colak, Gozde Harrison, Claire Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428431/ http://dx.doi.org/10.1097/01.HS9.0000967584.99278.43 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Passamonti, Francesco Patriarca, Andrea Knapper, Steven Rivera, Candido Scandura, Joseph M Devos, Timothy Granacher, Nikki Mead, Adam Oh, Stephen Palmer, Jeanne Rampal, Raajit K Teichmann, Lino LI, Qing Eliane, Jean-Pierre Chang, Tzuu-Wang Klein, Sandra Colak, Gozde Harrison, Claire S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY |
| title | S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY |
| title_full | S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY |
| title_fullStr | S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY |
| title_full_unstemmed | S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY |
| title_short | S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY |
| title_sort | s168: pelabresib (cpi-0610) monotherapy in patients with high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: preliminary results from manifest study |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428431/ http://dx.doi.org/10.1097/01.HS9.0000967584.99278.43 |
| work_keys_str_mv | AT passamontifrancesco s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy AT patriarcaandrea s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy AT knappersteven s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy AT riveracandido s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy AT scandurajosephm s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy AT devostimothy s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy AT granachernikki s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy AT meadadam s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy AT ohstephen s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy AT palmerjeanne s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy AT rampalraajitk s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy AT teichmannlino s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy AT liqing s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy AT elianejeanpierre s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy AT changtzuuwang s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy AT kleinsandra s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy AT colakgozde s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy AT harrisonclaire s168pelabresibcpi0610monotherapyinpatientswithhighriskessentialthrombocythemiarefractoryorintoleranttohydroxyureapreliminaryresultsfrommanifeststudy |